New Rapid COVID-19 Test Beats ELISA Method in Identifying SARS-CoV-2 Antibodies in Blood Within Just 12 Minutes
By LabMedica International staff writers Posted on 10 Feb 2021 |

Image: New Rapid COVID-19 Test Beats ELISA Method in Identifying SARS-CoV-2 Antibodies in Blood within Just 12 Minutes (Photo courtesy of American Chemical Society)
A new rapid COVID-19 test to detect coronavirus antibodies beats the enzyme linked immunosorbent assay (ELISA) method in delivering results within just 12 minutes, marking a milestone in the development of immunological diagnostics.
An international research team involving the University of Paraná (Paraná, Brazil) and the University of Tübingen (Tübingen, Germany) has developed the new rapid test that can reliably identify COVID-19 antibodies in the blood within minutes. The new process is based on a simple measuring principle, making it easy to carry out without expensive instruments and is therefore, suitable for use at mobile testing centers or by laboratories in less economically developed regions. The new diagnostic method is also far faster than the ELISA procedure, which for decades has been seen as the gold standard for laboratory diagnosis of antibodies.
The new test is based on magnetic nanoparticles that are coated with viral antigens. To conduct the test, blood serum or blood is applied to the test surface. After roughly two minutes, the nanoparticles are washed and treated with a developer reagent. If the blood sample displays antibodies to coronavirus, a color change occurs. While the traditional ELISA test produces results after about three hours, study results show that the new method only takes 12 minutes. Positive and negative results can be established simply with the naked eye, and by using additional instruments, such as a microplate reader, the precision of the test can be further increased. The total response time is 15 times shorter than that of the classic ELISA test, which means that hundreds of samples can be tested in just a few hours.
In addition, the study shows that the new technology can also be applied to the serological diagnosis of other diseases. There are no reports in research literature on an immunology test for COVID-19 that delivers data as quickly, as precisely and above all as cheaply. The researchers believe that it will be possible to offer the new test at a comparable price to the ELISA test in future.
“Only a small sample is needed for the test: a single drop that contains two microliters of serum is sufficient,” said the study’s lead author, Professor Luciano F. Huergo from the University of Paraná: “It’s also possible to use whole blood, in other words the separation of soluble blood components that is normally necessary can be omitted. It isn’t absolutely necessary to have a fully-equipped laboratory or use special equipment to carry it out.”
“Another advantage over the ELISA procedure is that the color result of our new procedure is directly proportional to the concentration of antibodies,” added Huergo. “In other words, the new method delivers data on the quantity of antibodies and not just whether any are present.”
Related Links:
University of Paraná
University of Tübingen
An international research team involving the University of Paraná (Paraná, Brazil) and the University of Tübingen (Tübingen, Germany) has developed the new rapid test that can reliably identify COVID-19 antibodies in the blood within minutes. The new process is based on a simple measuring principle, making it easy to carry out without expensive instruments and is therefore, suitable for use at mobile testing centers or by laboratories in less economically developed regions. The new diagnostic method is also far faster than the ELISA procedure, which for decades has been seen as the gold standard for laboratory diagnosis of antibodies.
The new test is based on magnetic nanoparticles that are coated with viral antigens. To conduct the test, blood serum or blood is applied to the test surface. After roughly two minutes, the nanoparticles are washed and treated with a developer reagent. If the blood sample displays antibodies to coronavirus, a color change occurs. While the traditional ELISA test produces results after about three hours, study results show that the new method only takes 12 minutes. Positive and negative results can be established simply with the naked eye, and by using additional instruments, such as a microplate reader, the precision of the test can be further increased. The total response time is 15 times shorter than that of the classic ELISA test, which means that hundreds of samples can be tested in just a few hours.
In addition, the study shows that the new technology can also be applied to the serological diagnosis of other diseases. There are no reports in research literature on an immunology test for COVID-19 that delivers data as quickly, as precisely and above all as cheaply. The researchers believe that it will be possible to offer the new test at a comparable price to the ELISA test in future.
“Only a small sample is needed for the test: a single drop that contains two microliters of serum is sufficient,” said the study’s lead author, Professor Luciano F. Huergo from the University of Paraná: “It’s also possible to use whole blood, in other words the separation of soluble blood components that is normally necessary can be omitted. It isn’t absolutely necessary to have a fully-equipped laboratory or use special equipment to carry it out.”
“Another advantage over the ELISA procedure is that the color result of our new procedure is directly proportional to the concentration of antibodies,” added Huergo. “In other words, the new method delivers data on the quantity of antibodies and not just whether any are present.”
Related Links:
University of Paraná
University of Tübingen
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more